방사선종양학

본문글자크기
  • [J Gynecol Oncol .] Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features

    성균관의대 /김나리, 박원*

  • 출처
    J Gynecol Oncol .
  • 등재일
    2021 Sep
  • 저널이슈번호
    32(5):e72. doi: 10.3802/jgo.2021.32.e72. Epub 2021 May 18.
  • 내용

    바로가기  >

    Abstract
    Objective: Unlike cervical squamous cell carcinoma, there are no consensus criteria for serum tumor markers in cervical adenocarcinoma. This study aimed to identify the prognostic value of preoperative carbohydrate antigen 125 (CA125) levels in cervical adenocarcinoma patients with adverse pathologic features.

    Methods: A total of 105 patients who underwent radical hysterectomy followed by adjuvant radiotherapy (RT) or concurrent chemoradiation therapy were included. Locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were evaluated using the Cox proportional hazard regression model.

    Results: Using a cutoff value of 50 U/mL, 83 and 22 patients had low- and high-CA125, respectively. Patients with high-CA125 had a larger tumor size, more frequent parametrial extension, and more frequent lymph node metastasis than those with low-CA125. During a median follow-up of 59.3 (interquartile range, 32.7-97.8) months, patients with high-CA125 showed inferior 5-year LRFS, DMFS, and OS rates compared to those with low-CA125 (38.5% vs. 70.0%; 37.0% vs. 69.4%; 43.6% vs. 78.1%, respectively, all p<0.05). In multivariable analysis, the high-CA125 remained significant prognostic factor for LRFS, DMFS, and OS (all p<0.05). Furthermore, 12 patients with high-CA125 at recurrence exhibited lower 5-year OS rates than 21 patients with low-CA125 at recurrence (0.0% vs. 51.3%, p=0.003).

    Conclusion: In this retrospective analysis, the serum CA125 level at diagnosis and recurrence was related to the extent of disease and prognosis of cervical adenocarcinoma with adverse pathologic features. A CA125 level of ≥50 U/mL may be a prognostic surrogate marker for cervical adenocarcinoma in patients with the presence of adverse factors.

     

     

    Affiliations

    Nalee Kim 1, Won Park 2, Won Kyung Cho 1, Duk Soo Bae 3, Byoung Gie Kim 3, Jeong Won Lee 3, Chel Hun Choi 3, Tae Joong Kim 3, Yoo Young Lee 3
    1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    2Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wonro.park@samsung.com.
    3Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

  • 키워드
    Adenocarcinoma; Carbohydrate Antigen 125; Cervical Cancer; Prognosis; Radiotherapy.
  • 덧글달기
    덧글달기
       IP : 3.236.138.35

    등록